Kintor Pharmaceutical Limited announced that the clinical trial of PD-L1/TGF-? dual-targeting antibody (GT90008) for the treatment of advanced solid tumours was approved by the National Medical Products Administration (NMPA) of China on 21 October 2021. GT90008 is a PD-L1/TGF-? dualtargeting antibody which has a high activity in inhibiting both PD-L1 and TGF-?R2. GT90008 has the potential to be a best-in-class drug globally. Kintor Pharma obtained an exclusive license in Greater China for GT90008 from US-based company Gensun in August 2020.